CytomX Therapeutics, Inc.

Good day, and thank you for standing by. Welcome to the Cytomics Therapeutics First Quarter 2024 Financial Results Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question-and-answer session. And to ask a question during the session, you will need to press star-one-one on your telephone, and you will then hear an automated message advising your hand is raised. To withdraw a question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Chris Ogden, Cytomics' Senior Vice President, Finance and Accounting. Please go ahead.

Thank you.

Good afternoon, and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. Earlier this afternoon, we issued a press release that includes a summary of our first quarter 2024 financial results and highlights recent progress at Cytomix. We also issued a press release today announcing positive initial phase 1a dose escalation data for monotherapy CX904, which will be the primary focus of today's call. We encourage everyone to read today's press releases and the associated materials which have been filed with the SEC. Additionally, the press releases or recording of this call and our SEC filings can be found under the Investors and News section of our website. With me on the call today are Dr. Sean McCarthy, Tectomics' Chief Executive Officer and Chairman, and Dr. Wayne Chu, Tectomics' Chief Medical Officer. Sean will provide an update on the overall pipeline and also outline Cytomix's broader strategy for mass T cell engagers. Wayne will then give an update on the CX904 phase one dose escalation study before Sean provides closing comments and we open up the call for Q&A. With that, I'll now turn the call over to Sean.